# Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

Source: https://onco.cc/trials/nct06299761/  
OnCo record `nct06299761` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BBI-825 run by Boundless Bio, Inc., terminated.

## Summary

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications is a phase 1 interventional study registered as NCT06299761 by Boundless Bio, Inc., with 19 participants enrolled, started 2024-03-28. Conditions recorded: Solid Tumor. Interventions recorded: BBI-825.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06299761
- Phase: 1
- Setting: An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-825 and BBI-825 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Resistance Gene Amplifications
- Sponsor: Boundless Bio, Inc.
- Enrolled: 19

## Sources

- ClinicalTrials.gov NCT06299761: https://clinicaltrials.gov/study/NCT06299761

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BBI-825](https://onco.cc/drugs/bbi-825/)
- companies: [Boundless Bio](https://onco.cc/companies/boundless-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct06299761.json